Acquirement

Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program

Eli Lilly and Company

Breakthrough Results

Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with Preserved Ejection Fraction

Eli Lilly and Company

M&A

Lilly Announces Acquisition of Protomer Technologies

Eli Lilly and Company

Phase III

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

Eli Lilly and Company

COVID-19

Lilly Modified COVID-19 Purchase Agreement for Bamlanivimab and Etesevimab Together

Eli Lilly and Company

FDA Authorization

Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19

Eli Lilly and Company

COVID-19

Lilly Announces Agreement with U.S. Government to Supply 300,000 Vials of Investigational Neutralizing Antibody to Fight COVID-19

Eli Lilly and Company

Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial

Eli Lilly and Company

Oncology

Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning

Eli Lilly and Company

New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.

Eli Lilly and Company

Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic

Eli Lilly and Company

Coronavirus

Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines

Eli Lilly and Company

Partnership

Eli Lilly and Company to Partner in Support of the Olympic and Paralympic Games Tokyo 2020

Eli Lilly and Company

Investment

Governor Cooper Announces Over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant

Eli Lilly and Company

M&A

Lilly Announces Agreement to Acquire Dermira

Eli Lilly and Company

Drug Pricing

Lilly Expands Insulin Affordability Options

Eli Lilly and Company

Investment

Lilly Announces $400 Million Capital Investment in Manufacturing Facilities in Indianapolis

Eli Lilly and Company

Phase III

Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis

Eli Lilly and Company

Licensing Agreement

Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China

Innovent